Arcturus Therapeutics remains a Hold as key mRNA pipeline data nears. Click here to read my most recent analysis of Arcturus stock.
Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Arcturus Therapeutics (ARCT) shares rose 6.3% in Thursday afternoon trading, a day after it reported
Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
Citi upgraded Arcturus to ‘Buy’ and raised the price target to $20 from $8, according to The Fly.
Arcturus (ARCT) reports phase 2 ARCT-810 results lowering ammonia in OTC deficiency and plans ARCT-2601 dosing with FDA input. Read more here.
SAN DIEGO, September 23, 2026--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company’s next-generation mRNA delivery platform, and additional liver pipeline programs.
Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.
SAN DIEGO, August 31, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences:
Is it a good or bad thing when a stock experiences a golden cross technical event?
Expanding oncology and rare disease pipelines, strategic partnerships, and advances in delivery technologies are expected to drive significant market growthDublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035" has been added to ResearchAndMar
This is the newest page. Registered accounts read further back.